Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Research & Development: 2010-2024

Historic Research & Development for Iovance Biotherapeutics (IOVA) over the last 12 years, with Dec 2024 value amounting to $282.3 million.

  • Iovance Biotherapeutics' Research & Development rose 12.14% to $75.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $308.5 million, marking a year-over-year increase of 4.10%. This contributed to the annual value of $282.3 million for FY2024, which is 17.94% down from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Research & Development of $282.3 million as of FY2024, which was down 17.94% from $344.1 million recorded in FY2023.
  • Over the past 5 years, Iovance Biotherapeutics' Research & Development peaked at $344.1 million during FY2023, and registered a low of $259.0 million during FY2021.
  • For the 3-year period, Iovance Biotherapeutics' Research & Development averaged around $307.1 million, with its median value being $294.8 million (2022).
  • Its Research & Development has fluctuated over the past 5 years, first rose by 16.72% in 2023, then fell by 17.94% in 2024.
  • Yearly analysis of 4 years shows Iovance Biotherapeutics' Research & Development stood at $259.0 million in 2021, then increased by 13.80% to $294.8 million in 2022, then grew by 16.72% to $344.1 million in 2023, then declined by 17.94% to $282.3 million in 2024.